504 related articles for article (PubMed ID: 18055849)
41. [Toxicosis of high-dose methotrexate (HD-MTX) for osteosarcoma, cured with treatment by leucovorin (LV) rescue and hemoperfusion--a case report].
Kobayashi H; Morita T; Hirata Y; Kato T; Okada Y; Sato T
Gan To Kagaku Ryoho; 2000 Mar; 27(3):475-8. PubMed ID: 10740644
[TBL] [Abstract][Full Text] [Related]
42. [Renal toxicity of high-dose methotrexate].
Garcia H; Leblond V; Goldwasser F; Bouscary D; Raffoux E; Boissel N; Broutin S; Joly D
Nephrol Ther; 2018 Apr; 14 Suppl 1():S103-S113. PubMed ID: 29606256
[TBL] [Abstract][Full Text] [Related]
43. Methotrexate levels and outcome in osteosarcoma.
Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic Drug Monitoring of Methotrexate in Plasma Using Ultra High-Performance Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry: Necessary After Administration of Glucarpidase in Methotrexate Intoxications.
Mulder MB; Huisman R; Engels FK; van der Sluis IM; Koch BCP
Ther Drug Monit; 2018 Aug; 40(4):383-385. PubMed ID: 29994985
[TBL] [Abstract][Full Text] [Related]
45. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2.
Widemann BC; Balis FM; Shalabi A; Boron M; O'Brien M; Cole DE; Jayaprakash N; Ivy P; Castle V; Muraszko K; Moertel CL; Trueworthy R; Hermann RC; Moussa A; Hinton S; Reaman G; Poplack D; Adamson PC
J Natl Cancer Inst; 2004 Oct; 96(20):1557-9. PubMed ID: 15494606
[TBL] [Abstract][Full Text] [Related]
46. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy.
Krause AS; Weihrauch MR; Bode U; Fleischhack G; Elter T; Heuer T; Engert A; Diehl V; Josting A
Leuk Lymphoma; 2002 Nov; 43(11):2139-43. PubMed ID: 12533039
[TBL] [Abstract][Full Text] [Related]
47. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.
Ramsey LB; Balis FM; O'Brien MM; Schmiegelow K; Pauley JL; Bleyer A; Widemann BC; Askenazi D; Bergeron S; Shirali A; Schwartz S; Vinks AA; Heldrup J
Oncologist; 2018 Jan; 23(1):52-61. PubMed ID: 29079637
[TBL] [Abstract][Full Text] [Related]
48. Carboxypeptidase G2 rescue in delayed methotrexate elimination in renal failure.
Mohty M; Peyriere H; Guinet C; Hillaire-Buys D; Blayac JP; Rossi JF
Leuk Lymphoma; 2000 Apr; 37(3-4):441-3. PubMed ID: 10752997
[TBL] [Abstract][Full Text] [Related]
49. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data.
Fukuhara K; Ikawa K; Morikawa N; Kumagai K
J Clin Pharm Ther; 2008 Dec; 33(6):677-84. PubMed ID: 19138246
[TBL] [Abstract][Full Text] [Related]
50. Leucovorin and maximum tolerated dose toxicity of methotrexate in rats.
Fuskevåg OM; Kristiansen C; Lindal S; Aarbakke J
Pediatr Hematol Oncol; 2000 Dec; 17(8):651-8. PubMed ID: 11127396
[TBL] [Abstract][Full Text] [Related]
51. [Severe renal impairment of methotrexate elimination after high dose therapy].
Lawrenz-Wolf B; Wolfrom C; Frickel C; Fengler R; Wehinger H; Henze G
Klin Padiatr; 1994; 206(4):319-26. PubMed ID: 7967432
[TBL] [Abstract][Full Text] [Related]
52. Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients.
Bressolle F; Bologna C; Kinowski JM; Arcos B; Sany J; Combe B
J Rheumatol; 1997 Oct; 24(10):1903-9. PubMed ID: 9330930
[TBL] [Abstract][Full Text] [Related]
53. Glucarpidase Intervention for Delayed Methotrexate Clearance.
Cavone JL; Yang D; Wang A
Ann Pharmacother; 2014 Jul; 48(7):897-907. PubMed ID: 24742398
[TBL] [Abstract][Full Text] [Related]
54. Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
Fermiano M; Bergsbaken J; Kolesar JM
Am J Health Syst Pharm; 2014 May; 71(10):793-8. PubMed ID: 24780487
[TBL] [Abstract][Full Text] [Related]
55. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
[TBL] [Abstract][Full Text] [Related]
56. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
Perez C; Wang YM; Sutow WW; Herson J
Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
[TBL] [Abstract][Full Text] [Related]
57. [Management recommendations in patients with methotrexate intoxication].
Schellens JH; Beijnen JH
Ned Tijdschr Geneeskd; 2007 Feb; 151(6):337-41. PubMed ID: 17352296
[TBL] [Abstract][Full Text] [Related]
58. [Cytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis].
Nakazaki S; Murayama T; Katoh S
Ryumachi; 2001 Dec; 41(6):929-37. PubMed ID: 11831013
[TBL] [Abstract][Full Text] [Related]
59. Anal submucosal injection: a novel modality for the treatment of advanced rectal cancer.
Shafik A; El-Metnawy W; El-Sibai O
Eur J Surg Oncol; 1999 Feb; 25(1):76-81. PubMed ID: 10188860
[TBL] [Abstract][Full Text] [Related]
60. Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study.
Schaff LR; Lobbous M; Carlow D; Schofield R; Gavrilovic IT; Miller AM; Stone JB; Piotrowski AF; Sener U; Skakodub A; Acosta EP; Ryan KJ; Mellinghoff IK; DeAngelis LM; Nabors LB; Grommes C
BMC Cancer; 2022 Jan; 22(1):60. PubMed ID: 35027038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
